Neuroimaging Markers of Motor and Nonmotor Features of Parkinson's Disease: An [18F]Fluorodeoxyglucose Positron Emission Computed Tomography Study

Aim: We sought to identify markers of motor and nonmotor function in Parkinson's disease (PD) using advanced neuroimaging techniques in subjects with PD. Methods: We enrolled 26 nondemented PD subjects and 12 control subjects. All subjects underwent [ 18 F]fluorodeoxyglucose positron emission c...

Full description

Saved in:
Bibliographic Details
Published inDementia and geriatric cognitive disorders Vol. 35; no. 3-4; pp. 183 - 196
Main Authors Huang, Chaorui, Ravdin, Lisa D., Nirenberg, Melissa J., Piboolnurak, Panida, Severt, Lawrence, Maniscalco, James S., Solnes, Lilja, Dorfman, Benjamin J., Henchcliffe, Claire
Format Journal Article
LanguageEnglish
Published Basel, Switzerland Karger 01.01.2013
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aim: We sought to identify markers of motor and nonmotor function in Parkinson's disease (PD) using advanced neuroimaging techniques in subjects with PD. Methods: We enrolled 26 nondemented PD subjects and 12 control subjects. All subjects underwent [ 18 F]fluorodeoxyglucose positron emission computed tomography (FDG-PET) and magnetic resonance imaging, and a complete neuropsychological battery. Results: FDG-PET of subjects with PD revealed significant metabolic elevations in the bilateral posterior lentiform nucleus, posterior cingulate, and parahippocampus, and metabolic reductions in the bilateral temporoparietal association cortex and occipital lobe versus controls. PD subjects had significant reductions in executive/attention function, memory/verbal learning, and speed of thinking, and significantly increased depression, anxiety and apathy scores compared with controls. Motor dysfunction correlated with increased metabolism in the posterior lentiform nucleus, pons, and cerebellum, and decreased metabolism in the temporoparietal lobe. Cognitive dysfunction correlated with increased posterior cingulate metabolism and decreased temporoparietal lobe metabolism. Depressive symptoms correlated with increased amygdala metabolism; anxiety scores correlated with decreased caudate metabolism, and apathy scores correlated with increased metabolism in the anterior cingulate and orbitofrontal lobe and decreased metabolism in the temporoparietal association cortex. Conclusions: Our findings showed that motor, cognitive, and emotional dysfunction in PD are associated with distinct patterns of cerebral metabolic changes.
AbstractList Aim: We sought to identify markers of motor and nonmotor function in Parkinson's disease (PD) using advanced neuroimaging techniques in subjects with PD. Methods: We enrolled 26 nondemented PD subjects and 12 control subjects. All subjects underwent [18F]fluorodeoxyglucose positron emission computed tomography (FDG-PET) and magnetic resonance imaging, and a complete neuropsychological battery. Results: FDG-PET of subjects with PD revealed significant metabolic elevations in the bilateral posterior lentiform nucleus, posterior cingulate, and parahippocampus, and metabolic reductions in the bilateral temporoparietal association cortex and occipital lobe versus controls. PD subjects had significant reductions in executive/attention function, memory/verbal learning, and speed of thinking, and significantly increased depression, anxiety and apathy scores compared with controls. Motor dysfunction correlated with increased metabolism in the posterior lentiform nucleus, pons, and cerebellum, and decreased metabolism in the temporoparietal lobe. Cognitive dysfunction correlated with increased posterior cingulate metabolism and decreased temporoparietal lobe metabolism. Depressive symptoms correlated with increased amygdala metabolism; anxiety scores correlated with decreased caudate metabolism, and apathy scores correlated with increased metabolism in the anterior cingulate and orbitofrontal lobe and decreased metabolism in the temporoparietal association cortex. Conclusions: Our findings showed that motor, cognitive, and emotional dysfunction in PD are associated with distinct patterns of cerebral metabolic changes.
Aim: We sought to identify markers of motor and nonmotor function in Parkinson's disease (PD) using advanced neuroimaging techniques in subjects with PD. Methods: We enrolled 26 nondemented PD subjects and 12 control subjects. All subjects underwent [ 18 F]fluorodeoxyglucose positron emission computed tomography (FDG-PET) and magnetic resonance imaging, and a complete neuropsychological battery. Results: FDG-PET of subjects with PD revealed significant metabolic elevations in the bilateral posterior lentiform nucleus, posterior cingulate, and parahippocampus, and metabolic reductions in the bilateral temporoparietal association cortex and occipital lobe versus controls. PD subjects had significant reductions in executive/attention function, memory/verbal learning, and speed of thinking, and significantly increased depression, anxiety and apathy scores compared with controls. Motor dysfunction correlated with increased metabolism in the posterior lentiform nucleus, pons, and cerebellum, and decreased metabolism in the temporoparietal lobe. Cognitive dysfunction correlated with increased posterior cingulate metabolism and decreased temporoparietal lobe metabolism. Depressive symptoms correlated with increased amygdala metabolism; anxiety scores correlated with decreased caudate metabolism, and apathy scores correlated with increased metabolism in the anterior cingulate and orbitofrontal lobe and decreased metabolism in the temporoparietal association cortex. Conclusions: Our findings showed that motor, cognitive, and emotional dysfunction in PD are associated with distinct patterns of cerebral metabolic changes.
Author Huang, Chaorui
Piboolnurak, Panida
Solnes, Lilja
Dorfman, Benjamin J.
Maniscalco, James S.
Severt, Lawrence
Ravdin, Lisa D.
Henchcliffe, Claire
Nirenberg, Melissa J.
Author_xml – sequence: 1
  givenname: Chaorui
  surname: Huang
  fullname: Huang, Chaorui
  email: chh2019@med.cornell.edu
– sequence: 2
  givenname: Lisa D.
  surname: Ravdin
  fullname: Ravdin, Lisa D.
– sequence: 3
  givenname: Melissa J.
  surname: Nirenberg
  fullname: Nirenberg, Melissa J.
– sequence: 4
  givenname: Panida
  surname: Piboolnurak
  fullname: Piboolnurak, Panida
– sequence: 5
  givenname: Lawrence
  surname: Severt
  fullname: Severt, Lawrence
– sequence: 6
  givenname: James S.
  surname: Maniscalco
  fullname: Maniscalco, James S.
– sequence: 7
  givenname: Lilja
  surname: Solnes
  fullname: Solnes, Lilja
– sequence: 8
  givenname: Benjamin J.
  surname: Dorfman
  fullname: Dorfman, Benjamin J.
– sequence: 9
  givenname: Claire
  surname: Henchcliffe
  fullname: Henchcliffe, Claire
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27146872$$DView record in Pascal Francis
BookMark eNptkU1P3DAQhq2KqnyUA3cOvlQVhxTbcRK7N7Rl20pAkQqnqoom_giGxF7ZjsT-DX4x6S7lUHUuM6N53leamX2044M3CB1R8onSSp4SQkpeSdG8QXuUM1pIwfjOpiaFIETsov2U7mesqWr5Du2ykvNqjj30dGWmGNwIvfM9voT4YGLCweLLkEPE4DW-Cn7cNEsDeYpmM76eSedT8B8T_uKSgWQ-4zOPf1Gx_L0cphCDNuFx3Q-TCsng65BcjsHj89Gl5OZiEcbVlI3GN2EMfYTV3Rr_zJNev0dvLQzJHL7kA3S7PL9ZfCsufnz9vji7KFTJ61zUnW4kU3VZNV3NKVG6Am2BdZ0U0tqKU0Y6BUxa0DXVwlRC19wSLS0R1qryAH3Y-q4gKRhsBK9caldxvkZct6yhvBYNm7nTLadiSCka2yqXIc875AhuaClp_3yhff3CrDj5R_HX9H_s8ZZ9gNib-Eq-jJ8BHr-Tdg
CitedBy_id crossref_primary_10_1002_hbm_25110
crossref_primary_10_3389_fnagi_2016_00289
crossref_primary_10_26442_20751753_2022_2_201507
crossref_primary_10_1159_000351421
crossref_primary_10_1016_j_jns_2016_10_021
crossref_primary_10_1007_s00259_019_04570_7
crossref_primary_10_1186_s13550_017_0317_9
crossref_primary_10_3389_fneur_2019_01204
crossref_primary_10_1002_mds_29565
crossref_primary_10_18632_oncotarget_18996
crossref_primary_10_1016_j_media_2022_102378
crossref_primary_10_1016_j_neubiorev_2018_10_004
crossref_primary_10_1007_s11910_017_0788_0
crossref_primary_10_3389_fneur_2019_00195
crossref_primary_10_3389_fnhum_2020_00193
crossref_primary_10_3390_jpm11070679
crossref_primary_10_1093_braincomms_fcae025
crossref_primary_10_5692_clinicalneurol_cn_001709
crossref_primary_10_1007_s11682_017_9764_1
crossref_primary_10_1111_cns_14214
crossref_primary_10_1016_j_jns_2016_12_062
crossref_primary_10_1111_ene_13002
crossref_primary_10_1016_S1474_4422_15_00019_8
crossref_primary_10_1016_j_neulet_2017_05_062
crossref_primary_10_1371_journal_pone_0236728
crossref_primary_10_2478_cpp_2022_0021
crossref_primary_10_1186_s13195_024_01429_4
crossref_primary_10_1177_0891988719882100
crossref_primary_10_1093_brain_awy110
crossref_primary_10_1016_j_nicl_2018_08_006
crossref_primary_10_1016_j_jpsychires_2017_02_010
crossref_primary_10_1007_s11910_019_0966_3
crossref_primary_10_1038_s41598_020_79138_9
crossref_primary_10_1016_j_brs_2020_12_008
crossref_primary_10_1093_neuros_nyz206
crossref_primary_10_1016_j_neulet_2018_06_043
crossref_primary_10_1016_j_neuropsychologia_2017_07_003
crossref_primary_10_1016_j_brainres_2020_147235
crossref_primary_10_1016_j_cortex_2019_09_011
crossref_primary_10_1038_s41531_019_0102_8
crossref_primary_10_1016_j_neubiorev_2016_08_012
crossref_primary_10_1159_000455930
crossref_primary_10_3389_fnagi_2014_00056
crossref_primary_10_1016_S1474_4422_18_30169_8
crossref_primary_10_1002_mds_28372
crossref_primary_10_1007_s11682_018_9959_0
crossref_primary_10_1097_MD_0000000000029931
crossref_primary_10_1002_gps_5255
crossref_primary_10_3389_fnins_2020_00025
crossref_primary_10_17116_jnevro20161163179_82
crossref_primary_10_14336_AD_2018_0814
crossref_primary_10_1016_j_pneurobio_2018_12_003
crossref_primary_10_1002_mds_28404
crossref_primary_10_1016_S1634_7072_19_42021_7
crossref_primary_10_1002_mds_26349
crossref_primary_10_1155_2017_6219851
crossref_primary_10_1111_cns_12493
crossref_primary_10_1007_s11910_018_0907_6
crossref_primary_10_1093_brain_awy257
crossref_primary_10_1007_s40266_022_00942_1
crossref_primary_10_1002_mds_26662
crossref_primary_10_1016_j_jns_2015_06_037
crossref_primary_10_1002_mds_26587
crossref_primary_10_1016_j_jchemneu_2024_102392
crossref_primary_10_1155_2016_9832839
crossref_primary_10_3233_JPD_150535
Cites_doi 10.1002%2Fmds.22833
10.1038%2Fnm0697-671
10.1159%2F000068483
10.1212%2FWNL.0b013e3182315259
10.1002%2Fmds.23268
10.1001%2Farchneur.60.12.1745
10.1002%2Fmds.21453
10.1097%2F00019052-199808000-00007
10.1016%2FS1474-4422%2809%2970293-5
10.1016%2F0022-3956%2875%2990026-6
10.1212%2FWNL.0b013e3181feb2ab
10.1097%2FNEN.0b013e31816362aa
10.1016%2Fj.pscychresns.2010.08.012
10.1016%2FS1053-8119%2803%2900168-X
10.1002%2Fmds.22760
10.1016%2Fj.jns.2011.07.006
10.1136%2Fjnnp.55.3.181
10.1159%2F000235247
10.1006%2Fnimg.2000.0582
10.1212%2F01.wnl.0000338632.00552.cb
10.1038%2Fjcbfm.1994.99
10.1212%2FWNL.0b013e3181f39d0e
10.1016%2Fj.parkreldis.2012.04.028
10.1016%2FS0022-510X%2899%2900127-6
10.1002%2Fmds.23664
10.1002%2Fmds.22611
10.1159%2F000315036
10.1007%2Fs13311-010-0007-z
10.1111%2Fj.1468-1331.2009.02707.x
10.1007%2Fs11910-011-0203-1
10.1016%2Fj.jns.2009.08.034
10.1002%2Fhbm.21378
10.1159%2F000323570
10.1212%2FWNL.0b013e3181c34b34
10.1002%2Fana.410280111
10.1212%2F01.wnl.0000269666.62598.1c
10.1097%2FWCO.0b013e32833b6019
10.1001%2Farchneur.64.7.1015
10.1002%2Fmds.10565
10.1093%2Fbrain%2Fawh445
10.1016%2FS1474-4422%2803%2900351-X
10.1093%2Fbrain%2Fawr031
10.1159%2F000336598
10.1007%2Fs00702-004-0168-1
10.1093%2Fbrain%2Fawm086
10.1177%2F0891988709351834
10.1192%2Fbjp.165.3.333
10.1136%2Fjnnp.2005.083113
10.1212%2F01.wnl.0000304050.05332.9c
10.1016%2F0165-1781%2891%2990040-V
10.1186%2F1471-2377-2-9
10.1212%2FWNL.0b013e3181a2e896
10.1007%2Fs00259-009-1259-x
10.1136%2Fjnnp.2006.100073
10.1093%2Fbrain%2F120.8.1315
10.1076%2Fclin.12.3.311.1992
ContentType Journal Article
Copyright 2013 S. Karger AG, Basel
2014 INIST-CNRS
Copyright_xml – notice: 2013 S. Karger AG, Basel
– notice: 2014 INIST-CNRS
DBID AAYXX
CITATION
IQODW
DOI 10.1159/000345987
DatabaseName CrossRef
Pascal-Francis
DatabaseTitle CrossRef
DatabaseTitleList CrossRef

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1421-9824
EndPage 196
ExternalDocumentID 27146872
10_1159_000345987
345987
GroupedDBID ---
.GJ
0-V
0R~
0~5
0~B
29F
30W
325
34G
36B
39C
3O.
3V.
4.4
53G
5GY
6PF
7RV
7X7
88E
88I
8AF
8AO
8FI
8FJ
8UI
AAWTL
AAYIC
ABIVO
ABJNI
ABPAZ
ABUWG
ACGFS
ACGOD
ACPRK
ACPSR
ADAGL
ADBBV
ADGES
AENEX
AEYAO
AFJJK
AFKRA
AHMBA
ALDHI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALSLI
AN0
ARALO
AZPMC
AZQEC
BENPR
BKEYQ
BNQBC
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CYUIP
DU5
DWQXO
E0A
EBS
EJD
EMB
EMOBN
EX3
F5P
FB.
FYUFA
GNUQQ
HCIFZ
HMCUK
HZ~
IAO
IHR
IHW
IY7
KUZGX
M1P
M2M
M2P
M2R
N9A
NAPCQ
O1H
O9-
P2P
PQQKQ
PROAC
PSQYO
PSYQQ
RIG
RKO
RXVBD
S0X
SV3
UJ6
UKHRP
WOW
AAYXX
ABBTS
ABWCG
ACQXL
AFSIO
AHFRZ
CITATION
ITC
PHGZM
PHGZT
IQODW
ID FETCH-LOGICAL-c346t-6bd792c6357b6410cd5adfa2bb989ff54120bca29fad61d8e58d64f0d9f08ffc3
ISSN 1420-8008
IngestDate Wed Apr 02 07:25:18 EDT 2025
Tue Jul 01 05:07:41 EDT 2025
Thu Apr 24 23:11:20 EDT 2025
Thu Aug 29 12:04:44 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 3-4
Keywords Glucose metabolism
Nonmotor features of Parkinson's disease
Cognition
Parkinson's disease
Emotion
Positron emission tomography
2-deoxy-2-fluoroglucose
Nervous system diseases
Cognitive disorder
Parkinson disease
Glucose
Metabolism
Cerebral disorder
Central nervous system disease
Degenerative disease
Extrapyramidal syndrome
Dementia
Emission tomography
Language English
License Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
https://www.karger.com/Services/SiteLicenses
CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c346t-6bd792c6357b6410cd5adfa2bb989ff54120bca29fad61d8e58d64f0d9f08ffc3
PMID 23445555
PageCount 14
ParticipantIDs crossref_citationtrail_10_1159_000345987
pascalfrancis_primary_27146872
karger_primary_345987
crossref_primary_10_1159_000345987
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-01-01
PublicationDateYYYYMMDD 2013-01-01
PublicationDate_xml – month: 01
  year: 2013
  text: 2013-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Basel, Switzerland
PublicationPlace_xml – name: Basel, Switzerland
– name: Basel
PublicationTitle Dementia and geriatric cognitive disorders
PublicationTitleAlternate Dement Geriatr Cogn Disord
PublicationYear 2013
Publisher Karger
Publisher_xml – name: Karger
References Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK: Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008;67:155-161.1821925410.1097%2FNEN.0b013e31816362aa
Benoit M, Robert PH: Imaging correlates of apathy and depression in Parkinson's disease. J Neurol Sci 2011;310:58-60.2183140010.1016%2Fj.jns.2011.07.006
Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA: Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009;8:1128-1139.1990991110.1016%2FS1474-4422%2809%2970293-5
Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S: The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801.806387410.1038%2Fjcbfm.1994.99
Bosboom JL, Stoffers D, Wolters E: Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 2004;111:1303-1315.1548084010.1007%2Fs00702-004-0168-1
Reitan RRM, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, Neuropsychology Press, 1992.
Huang C, Wahlund LO, Almkvist O, Elehu D, Svensson L, Jonsson T, Winblad B, Julin P: Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage 2003;19:1137-1144.1288083910.1016%2FS1053-8119%2803%2900168-X
Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G: Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009;72:1121-1126.1902029310.1212%2F01.wnl.0000338632.00552.cb
Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS: Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur Neurol 2010;64:65-73.2060645010.1159%2F000315036
Marin R, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143-162.175462910.1016%2F0165-1781%2891%2990040-V
Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, Wiley, 1989.
Stoessl AJ: Neuroimaging in Parkinson's disease. Neurotherapeutics 2011;8:72-81.2127468710.1007%2Fs13311-010-0007-z
Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D: Changes in network activity with the progression of Parkinson's disease. Brain 2007;130:1834-1846.1747049510.1093%2Fbrain%2Fawm086
Wechsler D: Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) 1997; San Antonio, TX: The Psychological Corporation.
Appel-Cresswell S, de la Fuente-Fernandez R, Galley S, McKeown MJ: Imaging of compensatory mechanisms in Parkinson's disease. Curr Opin Neurol 2010;23:407-412.2061099110.1097%2FWCO.0b013e32833b6019
Le Jeune F, Drapier D, Bourguignon A, Peron J, Mesbah H, Drapier S, Sauleau P, Haegelen C, Travers D, Garin E, Malbert CH, Millet B Verin M: Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009;73:1746-1751.1993397510.1212%2FWNL.0b013e3181c34b34
Goldon C: Stroop Color and Word Test. Chicago, Stoelting Company, 1978.
Berti V, Polito C, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, Mungai F, Marini P, Formiconi AR, Sorbi S, Pupi A: Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging 2010;37:537-544.1972771210.1007%2Fs00259-009-1259-x
Fahn S, Elton R, the Members of the Unified Parkinson's Disease Rating Scale Development Commitee: Unified Parkinson's Disease Rating Scale; in Fahn CD, Calne DB, Goldstein M (eds): Recent Developments in Parkinson's Disease. New York, MacMillan, 1987.
Beck AT, Steer RA: Beck Anxiety Inventory Manual. San Antonio, The Psychological Corporation, 1990.
Kaplan E, Goodglass H, Weintraub S: The Boston Naming Test. Boston, Kaplan and Goodglass, 1978.
Pereira JB, Ibarretxe-Bilbao N, Marti MJ, Compta Y, Junque C, Bargallo N, Tolosa E: Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapp 2012;33:2521-2534.2189867910.1002%2Fhbm.21378
Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P: Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010;75:1920-1927.2109840710.1212%2FWNL.0b013e3181feb2ab
Remy P, Doder M, Lees A, Turjanski N, Brooks D: Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314-1322.1571630210.1093%2Fbrain%2Fawh445
Huang C, Wahlund LO, Svensson L, Winblad B, Julin P: Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurol 2002;2:9.1222783310.1186%2F1471-2377-2-9
Broussolle E, Dentresangle C, Landais P, Garcia-Larrea L, Pollak P, Croisile B, Hibert O, Bonnefoi F, Galy G, Froment JC, Comar D: The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci 1999;166:141-151.1047510810.1016%2FS0022-510X%2899%2900127-6
Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M: Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062-1069.2085584910.1212%2FWNL.0b013e3181f39d0e
Compta Y, Ibarretxe-Bilbao N, Pereira JB, Junque C, Bargallo N, Tolosa E, Valldeoriola F, Munoz E, Camara A, Buongiorno M, Marti MJ: Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat Disord 2012;18:941-947.2259562110.1016%2Fj.parkreldis.2012.04.028
Eidelberg D, Moeller JR, Kazumata K, Antonini A, Sterio D, Dhawan V, Spetsieris P, Alterman R, Kelly PJ, Dogali M, Fazzini E, Beric A: Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 1997;120:1315-1324.927862510.1093%2Fbrain%2F120.8.1315
Emre M: Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-237.1284921110.1016%2FS1474-4422%2803%2900351-X
Dissanayaka NN, Sellbach A, Matheson S, O'Sullivan JD, Silburn PA, Byrne GJ, Marsh R, Mellick GD: Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 2010;25:838-845.2046180010.1002%2Fmds.22833
Janvin C, Aarsland D, Larsen JP, Hugdahl K: Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord 2003;15:126-131.1258442710.1159%2F000068483
Aarsland D, Kurz MW: The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010;289:18-22.1973336410.1016%2Fj.jns.2009.08.034
Beyer MK, Larsen JP, Aarsland D: Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 2007;69:747-754.1770970610.1212%2F01.wnl.0000269666.62598.1c
Benton AL, Hamsher K, Sivan AB: Manual for the Multilingual Aphasia Examination, ed 3. Iowa City, AJA Associates, Inc, 1994.
Saur R, Maier C, Milian M, Riedel E, Berg D, Liepelt-Scarfone I, Leyhe T: Clock test deficits related to the global cognitive state in Alzheimer's and Parkinson's disease. Dement Geriatr Cogn Disord 2012;33:59-72.2241521110.1159%2F000336598
Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ: Depression in Parkinson's disease. A positron emission study. Br J Psychiatry 1994;165:333-339.799450210.1192%2Fbjp.165.3.333
Oguru M, Tachibana H, Toda K, Okuda B, Oka N: Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol 2010;23:35-41.2001583910.1177%2F0891988709351834
Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL: Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78:36-42.1682042110.1136%2Fjnnp.2005.083113
Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.156447610.1136%2Fjnnp.55.3.181
Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL: Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 2007;64:1015-1020.1762049310.1001%2Farchneur.64.7.1015
Winegarden BJ, Yates BL, Moses JJA, Benton AL, Faustman WO: Development of an optimally reliable short form for judgment of line orientation. Clin Neuropsychol 1998;12:311-314.10.1076%2Fclin.12.3.311.1992
Weintraub D, Burn DJ: Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 2011;26:1022-1031.2162654710.1002%2Fmds.23664
Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH: Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-1277.1741579710.1002%2Fmds.21453
Beck AT, Steer RA, Brown GK: Beck Depression Inventory, ed 2. San Antonio, The Psychological Corporation, 1996.
Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, Wagner HN Jr, Robinson RG: Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 1990;28:57-64.237563410.1002%2Fana.410280111
Reijnders JS, Scholtissen B, Weber WE, Aalten P, Verhey FR, Leentjens AF: Neuroanatomical correlates of apathy in Parkinson's disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord 2010;25:2318-2325.2066926410.1002%2Fmds.23268
Johnson DK, Galvin JE: Longitudinal changes in cognition in Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord 2011;31:98-108.2124269110.1159%2F000323570
Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D: Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;70:1470-1477.1836770510.1212%2F01.wnl.0000304050.05332.9c
Frisoni GB, Lorenzi M, Caroli
ref13
ref12
ref56
ref15
ref14
ref53
ref52
ref11
ref55
ref10
ref54
ref17
ref16
ref19
ref18
ref51
ref50
ref46
ref45
ref48
ref47
ref42
ref41
ref44
ref43
ref49
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref40
ref35
ref34
ref37
ref36
ref31
ref30
ref33
ref32
ref2
ref1
ref39
ref38
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
References_xml – reference: Berti V, Polito C, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, Mungai F, Marini P, Formiconi AR, Sorbi S, Pupi A: Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging 2010;37:537-544.1972771210.1007%2Fs00259-009-1259-x
– reference: Reijnders JS, Scholtissen B, Weber WE, Aalten P, Verhey FR, Leentjens AF: Neuroanatomical correlates of apathy in Parkinson's disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord 2010;25:2318-2325.2066926410.1002%2Fmds.23268
– reference: Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH: Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-1277.1741579710.1002%2Fmds.21453
– reference: McKinlay A, Grace RC, Dalrymple-Alford JC, Roger D: Cognitive characteristics associated with mild cognitive impairment in Parkinson's disease. Dement Geriatr Cogn Disord 2009;28:121-129.1969041410.1159%2F000235247
– reference: Fahn S, Elton R, the Members of the Unified Parkinson's Disease Rating Scale Development Commitee: Unified Parkinson's Disease Rating Scale; in Fahn CD, Calne DB, Goldstein M (eds): Recent Developments in Parkinson's Disease. New York, MacMillan, 1987.
– reference: Johnson DK, Galvin JE: Longitudinal changes in cognition in Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord 2011;31:98-108.2124269110.1159%2F000323570
– reference: Elgh E, Domellof M, Linder J, Edstrom M, Stenlund H, Forsgren L: Cognitive function in early Parkinson's disease: a population-based study. Eur J Neurol 2009;16:1278-1284.1953820810.1111%2Fj.1468-1331.2009.02707.x
– reference: Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D: Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;70:1470-1477.1836770510.1212%2F01.wnl.0000304050.05332.9c
– reference: Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, Wagner HN Jr, Robinson RG: Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 1990;28:57-64.237563410.1002%2Fana.410280111
– reference: Winegarden BJ, Yates BL, Moses JJA, Benton AL, Faustman WO: Development of an optimally reliable short form for judgment of line orientation. Clin Neuropsychol 1998;12:311-314.10.1076%2Fclin.12.3.311.1992
– reference: Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.120220410.1016%2F0022-3956%2875%2990026-6
– reference: Apostolova I, Block S, Buchert R, Osen B, Conradi M, Tabrizian S, Gensichen S, Schroder-Hartwig K, Fricke S, Rufer M, Weiss A, Hand I, Clausen M, Obrocki J: Effects of behavioral therapy or pharmacotherapy on brain glucose metabolism in subjects with obsessive-compulsive disorder as assessed by brain FDG PET. Psychiatry Res 2010;184:105-116.2094731710.1016%2Fj.pscychresns.2010.08.012
– reference: Goldon C: Stroop Color and Word Test. Chicago, Stoelting Company, 1978.
– reference: Blonder LX, Slevin JT: Emotional dysfunction in Parkinson's disease. Behav Neurol 2011;24:201-217.21876260
– reference: Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK: Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008;67:155-161.1821925410.1097%2FNEN.0b013e31816362aa
– reference: Weintraub D, Burn DJ: Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 2011;26:1022-1031.2162654710.1002%2Fmds.23664
– reference: Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T: Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134:1493-505.2159677310.1093%2Fbrain%2Fawr031
– reference: Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA: Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009;8:1128-1139.1990991110.1016%2FS1474-4422%2809%2970293-5
– reference: Huang C, Wahlund LO, Svensson L, Winblad B, Julin P: Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurol 2002;2:9.1222783310.1186%2F1471-2377-2-9
– reference: Beck AT, Steer RA: Beck Anxiety Inventory Manual. San Antonio, The Psychological Corporation, 1990.
– reference: Remy P, Doder M, Lees A, Turjanski N, Brooks D: Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314-1322.1571630210.1093%2Fbrain%2Fawh445
– reference: Le Jeune F, Drapier D, Bourguignon A, Peron J, Mesbah H, Drapier S, Sauleau P, Haegelen C, Travers D, Garin E, Malbert CH, Millet B Verin M: Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009;73:1746-1751.1993397510.1212%2FWNL.0b013e3181c34b34
– reference: Janvin C, Aarsland D, Larsen JP, Hugdahl K: Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord 2003;15:126-131.1258442710.1159%2F000068483
– reference: Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Nagren K, Rinne JO: In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 2009;72:1504-1511.1939870510.1212%2FWNL.0b013e3181a2e896
– reference: Reitan RRM, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, Neuropsychology Press, 1992.
– reference: Emre M: Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-237.1284921110.1016%2FS1474-4422%2803%2900351-X
– reference: Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS: Cerebral glucose metabolism of Parkinson's disease patients with mild cognitive impairment. Eur Neurol 2010;64:65-73.2060645010.1159%2F000315036
– reference: Smith A: Symbol Digit Modalities Test (SDMT) Manual (Revised). Los Angeles, Western Psychological Services, 1982.
– reference: Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL: Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78:36-42.1682042110.1136%2Fjnnp.2005.083113
– reference: Aarsland D, Bronnick K, Fladby T: Mild cognitive impairment in Parkinson's disease. Curr Neurol Neurosci Rep 2011;11:371-378.2148773010.1007%2Fs11910-011-0203-1
– reference: Aarsland D, Kurz MW: The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010;289:18-22.1973336410.1016%2Fj.jns.2009.08.034
– reference: Goodglass H, Kaplan E: Assessment of Aphasia and Related Disorders, ed 2. Philadelphia, Lea and Febiger, 1983.
– reference: Beyer MK, Larsen JP, Aarsland D: Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 2007;69:747-754.1770970610.1212%2F01.wnl.0000269666.62598.1c
– reference: Beck AT, Steer RA, Brown GK: Beck Depression Inventory, ed 2. San Antonio, The Psychological Corporation, 1996.
– reference: Negre-Pages L, Grandjean H, Lapeyre-Mestre M, Montastruc JL, Fourrier A, Lepine JP, Rascol O: Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study. Mov Disord 2010;25:157-166.1995040310.1002%2Fmds.22760
– reference: Saur R, Maier C, Milian M, Riedel E, Berg D, Liepelt-Scarfone I, Leyhe T: Clock test deficits related to the global cognitive state in Alzheimer's and Parkinson's disease. Dement Geriatr Cogn Disord 2012;33:59-72.2241521110.1159%2F000336598
– reference: Appel-Cresswell S, de la Fuente-Fernandez R, Galley S, McKeown MJ: Imaging of compensatory mechanisms in Parkinson's disease. Curr Opin Neurol 2010;23:407-412.2061099110.1097%2FWCO.0b013e32833b6019
– reference: Bohnen NI, Kaufer DI, Hendrickson R, Constantine GM, Mathis CA, Moore RY: Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry 2007;78:641-643.1750744710.1136%2Fjnnp.2006.100073
– reference: Broussolle E, Dentresangle C, Landais P, Garcia-Larrea L, Pollak P, Croisile B, Hibert O, Bonnefoi F, Galy G, Froment JC, Comar D: The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci 1999;166:141-151.1047510810.1016%2FS0022-510X%2899%2900127-6
– reference: Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P: Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010;75:1920-1927.2109840710.1212%2FWNL.0b013e3181feb2ab
– reference: Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D: Changes in network activity with the progression of Parkinson's disease. Brain 2007;130:1834-1846.1747049510.1093%2Fbrain%2Fawm086
– reference: Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M: Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062-1069.2085584910.1212%2FWNL.0b013e3181f39d0e
– reference: Pappata S, Santangelo G, Aarsland D, Vicidomini C, Longo K, Bronnick K, Amboni M, Erro R, Vitale C, Caprio MG, Pellecchia MT, Brunetti A, De Michele G, Salvatore M, Barone P: Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 2011;77:1357-1362.2194062110.1212%2FWNL.0b013e3182315259
– reference: Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S: The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801.806387410.1038%2Fjcbfm.1994.99
– reference: Benoit M, Robert PH: Imaging correlates of apathy and depression in Parkinson's disease. J Neurol Sci 2011;310:58-60.2183140010.1016%2Fj.jns.2011.07.006
– reference: Benton AL, Hamsher K, Sivan AB: Manual for the Multilingual Aphasia Examination, ed 3. Iowa City, AJA Associates, Inc, 1994.
– reference: Emre M: What causes mental dysfunction in Parkinson's disease? Mov Disord 2003;18(suppl 6):S63-S71.1450265810.1002%2Fmds.10565
– reference: Oguru M, Tachibana H, Toda K, Okuda B, Oka N: Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol 2010;23:35-41.2001583910.1177%2F0891988709351834
– reference: Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL: Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 2007;64:1015-1020.1762049310.1001%2Farchneur.64.7.1015
– reference: Eidelberg D, Moeller JR, Kazumata K, Antonini A, Sterio D, Dhawan V, Spetsieris P, Alterman R, Kelly PJ, Dogali M, Fazzini E, Beric A: Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 1997;120:1315-1324.927862510.1093%2Fbrain%2F120.8.1315
– reference: Ashburner J, Friston KJ: Voxel-based morphometry - the methods. Neuroimage 2000;11:805-821.1086080410.1006%2Fnimg.2000.0582
– reference: Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G: Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009;72:1121-1126.1902029310.1212%2F01.wnl.0000338632.00552.cb
– reference: Pontone GM, Williams JR, Anderson KE, Chase G, Goldstein SA, Grill S, Hirsch ES, Lehmann S, Little JT, Margolis RL, Rabins PV, Weiss HD, Marsh L: Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord 2009;24:1333-1338.1942508610.1002%2Fmds.22611
– reference: Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.156447610.1136%2Fjnnp.55.3.181
– reference: Dissanayaka NN, Sellbach A, Matheson S, O'Sullivan JD, Silburn PA, Byrne GJ, Marsh R, Mellick GD: Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 2010;25:838-845.2046180010.1002%2Fmds.22833
– reference: Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, Wiley, 1989.
– reference: Compta Y, Ibarretxe-Bilbao N, Pereira JB, Junque C, Bargallo N, Tolosa E, Valldeoriola F, Munoz E, Camara A, Buongiorno M, Marti MJ: Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat Disord 2012;18:941-947.2259562110.1016%2Fj.parkreldis.2012.04.028
– reference: Wechsler D: Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) 1997; San Antonio, TX: The Psychological Corporation.
– reference: Pereira JB, Ibarretxe-Bilbao N, Marti MJ, Compta Y, Junque C, Bargallo N, Tolosa E: Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapp 2012;33:2521-2534.2189867910.1002%2Fhbm.21378
– reference: Bosboom JL, Stoffers D, Wolters E: Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 2004;111:1303-1315.1548084010.1007%2Fs00702-004-0168-1
– reference: Huang C, Wahlund LO, Almkvist O, Elehu D, Svensson L, Jonsson T, Winblad B, Julin P: Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage 2003;19:1137-1144.1288083910.1016%2FS1053-8119%2803%2900168-X
– reference: Turner RS, Grafton ST, Votaw JR, Delong MR, Hoffman JM: Motor subcircuits mediating the control of movement velocity: a PET study. J Neurophysiol 1998;80:2162-2176.9772269
– reference: Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST: Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-1748.1467605010.1001%2Farchneur.60.12.1745
– reference: Delis DC, Kramer J, Kaplan E, Ober B: The California Verbal Learning Test, ed 2. San Antonio, The Psychological Corporation, 2000.
– reference: Kaplan E, Goodglass H, Weintraub S: The Boston Naming Test. Boston, Kaplan and Goodglass, 1978.
– reference: Marin R, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143-162.175462910.1016%2F0165-1781%2891%2990040-V
– reference: Mattis S: Dementia Rating Scale. Odessa, The Psychological Corporation, 1988.
– reference: Eidelberg D: Functional brain networks in movement disorders. Curr Opin Neurol 1998;11:319-326.972507710.1097%2F00019052-199808000-00007
– reference: Stoessl AJ: Neuroimaging in Parkinson's disease. Neurotherapeutics 2011;8:72-81.2127468710.1007%2Fs13311-010-0007-z
– reference: Davis KD, Taub E, Houle S, Lang AE, Dostrovsky JO, Tasker RR, Lozano AM: Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. Nat Med 1997;3:671-674.917649510.1038%2Fnm0697-671
– reference: Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ: Depression in Parkinson's disease. A positron emission study. Br J Psychiatry 1994;165:333-339.799450210.1192%2Fbjp.165.3.333
– ident: ref44
  doi: 10.1002%2Fmds.22833
– ident: ref21
  doi: 10.1038%2Fnm0697-671
– ident: ref14
  doi: 10.1159%2F000068483
– ident: ref24
  doi: 10.1212%2FWNL.0b013e3182315259
– ident: ref53
  doi: 10.1002%2Fmds.23268
– ident: ref47
  doi: 10.1001%2Farchneur.60.12.1745
– ident: ref10
  doi: 10.1002%2Fmds.21453
– ident: ref56
  doi: 10.1097%2F00019052-199808000-00007
– ident: ref1
  doi: 10.1016%2FS1474-4422%2809%2970293-5
– ident: ref30
  doi: 10.1016%2F0022-3956%2875%2990026-6
– ident: ref48
  doi: 10.1212%2FWNL.0b013e3181feb2ab
– ident: ref41
  doi: 10.1097%2FNEN.0b013e31816362aa
– ident: ref51
  doi: 10.1016%2Fj.pscychresns.2010.08.012
– ident: ref55
  doi: 10.1016%2FS1053-8119%2803%2900168-X
– ident: ref50
  doi: 10.1002%2Fmds.22760
– ident: ref52
  doi: 10.1016%2Fj.jns.2011.07.006
– ident: ref29
  doi: 10.1136%2Fjnnp.55.3.181
– ident: ref13
  doi: 10.1159%2F000235247
– ident: ref33
  doi: 10.1006%2Fnimg.2000.0582
– ident: ref9
  doi: 10.1212%2F01.wnl.0000338632.00552.cb
– ident: ref20
  doi: 10.1038%2Fjcbfm.1994.99
– ident: ref3
  doi: 10.1212%2FWNL.0b013e3181f39d0e
– ident: ref35
  doi: 10.1016%2Fj.parkreldis.2012.04.028
– ident: ref37
  doi: 10.1016%2FS0022-510X%2899%2900127-6
– ident: ref6
  doi: 10.1002%2Fmds.23664
– ident: ref43
  doi: 10.1002%2Fmds.22611
– ident: ref25
  doi: 10.1159%2F000315036
– ident: ref19
  doi: 10.1007%2Fs13311-010-0007-z
– ident: ref11
  doi: 10.1111%2Fj.1468-1331.2009.02707.x
– ident: ref12
  doi: 10.1007%2Fs11910-011-0203-1
– ident: ref8
  doi: 10.1016%2Fj.jns.2009.08.034
– ident: ref34
  doi: 10.1002%2Fhbm.21378
– ident: ref16
  doi: 10.1159%2F000323570
– ident: ref28
  doi: 10.1212%2FWNL.0b013e3181c34b34
– ident: ref26
  doi: 10.1002%2Fana.410280111
– ident: ref36
  doi: 10.1212%2F01.wnl.0000269666.62598.1c
– ident: ref39
  doi: 10.1097%2FWCO.0b013e32833b6019
– ident: ref54
  doi: 10.1001%2Farchneur.64.7.1015
– ident: ref2
  doi: 10.1002%2Fmds.10565
– ident: ref49
  doi: 10.1093%2Fbrain%2Fawh445
– ident: ref4
  doi: 10.1016%2FS1474-4422%2803%2900351-X
– ident: ref42
  doi: 10.1093%2Fbrain%2Fawr031
– ident: ref7
  doi: 10.1159%2F000336598
– ident: ref15
  doi: 10.1007%2Fs00702-004-0168-1
– ident: ref17
  doi: 10.1093%2Fbrain%2Fawm086
– ident: ref45
  doi: 10.1177%2F0891988709351834
– ident: ref27
  doi: 10.1192%2Fbjp.165.3.333
– ident: ref5
  doi: 10.1136%2Fjnnp.2005.083113
– ident: ref23
  doi: 10.1212%2F01.wnl.0000304050.05332.9c
– ident: ref32
  doi: 10.1016%2F0165-1781%2891%2990040-V
– ident: ref38
  doi: 10.1186%2F1471-2377-2-9
– ident: ref40
  doi: 10.1212%2FWNL.0b013e3181a2e896
– ident: ref22
  doi: 10.1007%2Fs00259-009-1259-x
– ident: ref46
  doi: 10.1136%2Fjnnp.2006.100073
– ident: ref18
  doi: 10.1093%2Fbrain%2F120.8.1315
– ident: ref31
  doi: 10.1076%2Fclin.12.3.311.1992
SSID ssj0007569
Score 2.348333
Snippet Aim: We sought to identify markers of motor and nonmotor function in Parkinson's disease (PD) using advanced neuroimaging techniques in subjects with PD....
SourceID pascalfrancis
crossref
karger
SourceType Index Database
Enrichment Source
Publisher
StartPage 183
SubjectTerms Biological and medical sciences
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Investigative techniques, diagnostic techniques (general aspects)
Medical sciences
Nervous system
Neurology
Original Research Article
Radionuclide investigations
Title Neuroimaging Markers of Motor and Nonmotor Features of Parkinson's Disease: An [18F]Fluorodeoxyglucose Positron Emission Computed Tomography Study
URI https://karger.com/doi/10.1159/000345987
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9NAFB7KKuKL6LrielkGcVehW23SmVx8S7ctrWvTUrZSWKQkmYwston0Ataf4d_yT3nmkknrLnh5CW0yNEnPl5lzTr7zHYRecjdibiOGMBXQUCOObdW8lCa1yPJ8h3IScdm1pB863TF5P6GTSuXnFmtpvYrfJN9vrCv5H6vCPrCrqJL9B8uaH4Ud8BnsC1uwMGz_ysZSWeNqrhoNiaobUY0rOC35SnMjwzybyy_C1VsvlMKsqHTWRV_uUuhvilc0OkN4TJuW1zmmrc5sncPkmubfNgWtfSgIXguASxvAIbJsVd0TQrBx5lr7WjITd94Vt2QGUhV_VT-L_0V0BaiWxCWmFUCNe3_WDQajca_aHQeh6f01Cj62eqHKIyyjkqkc9kbtsNkeydqrfjqDS4vKl13DXnMw-BCOR8G5cpizK52D0KkO0XZiJ9VxLrjxi63JmkDoCw6vtz2bK_ETjdqigkhNzpZqmaPXeUt10r2-hFBfcS4bhPraGdiR6f5t-TSkRtsVZWwu-AO3bIhZRDsNd2Kif3DNZH9Fc9Fa5gpO99acbMc5uv1F3q9g60ZLeGC56rSy5f5c3Ef3dNyCAwXCB6iSZvvoTl8zM_bRyVBpoG9O8UVZ0rc8xSd4WKqjbx6iH9ugxRq0OOdYghYDRnABWlyAVhw2oH21xBqy73CQ4UuA66frYMUFWHEBVlyAFZdgxRKsB2jcaV-cdWu6MUgtaRBnVXNi5vp2IqQUY4dY9YTRiPHIjmPf8zmnxLLrcRLZPo-YYzGYfDzmEF5nPq97nCeNR2gvy7P0McKuQ2JweX3mWYT4nMUND2JOltAU_HRO64fodWGRaaJV80XzltlURs_UnxrjHaIXZuhXJRVz06ADZVYzpNh_tGNlc7hA1ZM_DXiK7pbPzDO0t1qs0-fgMK_iIwnEXz9yxGQ
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neuroimaging+Markers+of+Motor+and+Nonmotor+Features+of+Parkinson%27s+Disease%3A+An+%5B18F%5DFluorodeoxyglucose+Positron+Emission+Computed+Tomography+Study&rft.jtitle=Dementia+and+geriatric+cognitive+disorders&rft.au=CHAORUI+HUANG&rft.au=RAVDIN%2C+Lisa+D&rft.au=NIRENBERG%2C+Melissa+J&rft.au=PIBOOLNURAK%2C+Panida&rft.date=2013-01-01&rft.pub=Karger&rft.issn=1420-8008&rft.volume=35&rft.issue=3-4&rft.spage=183&rft.epage=196&rft_id=info:doi/10.1159%2F000345987&rft.externalDBID=n%2Fa&rft.externalDocID=27146872
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1420-8008&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1420-8008&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1420-8008&client=summon